The ServierONE patient support program provides patients with financial assistance and one-on-one support when prescribed a Servier oncology product (Table).
ServierONE Patient Support Services
This program offers several patient support services to help patients throughout their treatment journey.
Free Product Program/Financial Assistance Program
Servier offers financial support for patients taking Asparlas and Oncaspar who meet eligibility requirements. To learn more, contact a Servier Case Manager at 800-813-5905 or email This email address is being protected from spambots. You need JavaScript enabled to view it..
ONE for ALL
This site was designed for patients and their families and provides helpful resources and tools for navigating treatment care, costs, and education. ONE for ALL.
This program provides a free 30-day prescription to eligible new patients experiencing coverage delays. To apply on behalf of patients, visit: Tibsovo QuickStart Program.
ONE for CCA
This site was designed for patients and provides helpful resources and tools for navigating treatment care, costs, and education. One for CCA.
TABLE Servier Oncology Drugs
Drugs
Indications
Patient support programs
Drug
Asparlas (calaspargase pegol-mknl)
Indications
As a component of a multiagent chemotherapeutic regimen for the treatment of pediatric and young adult patients (aged 1 month to 21 years) with acute lymphoblastic leukemia
As a component of a multiagent chemotherapeutic regimen for the treatment of pediatric and adult patients with acute lymphoblastic leukemia and hypersensitivity to native forms of L-asparaginase
In combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test in adults aged ≥75 years, or who have comorbidities that preclude use of intensive induction chemotherapy; treatment of adult patients with relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test; treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test
